A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors

In the last 3 years, a novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors...

Full description

Saved in:
Bibliographic Details
Main Authors: Mariane Teodoro Fernandes (Author), Jacob J Adashek (Author), Carmelia Maria Noia Barreto (Author), Ana Cláudia Barbin Spinosa (Author), Barbara de Souza Gutierres (Author), Gilberto Lopes (Author), Auro del Giglio (Author), Pedro Nazareth Aguiar Jr (Author)
Format: Book
Published: BioExcel Publishing Ltd, 2018-11-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items